MiniMed plans to develop a fully automated insulin-pump system that functions as the “self-driving car” of diabetes care [1].
This initiative seeks to shift the burden of disease management from the patient to the technology. By automating insulin delivery, the company aims to improve health outcomes and remove the constant manual calculations required by people living with diabetes [2].
Que Dallara, CEO of MiniMed, said this vision during an interview at the Consello Spark Summit on May 15 [1]. The announcement follows the company's initial public offering, signaling a strategic push toward higher levels of autonomy in medical devices [1].
“We want to be the self-driving car of insulin pumps,” Dallara said [1].
The proposed system would operate as a hands-free solution for insulin management [2]. Current automated systems often require user input or periodic calibration, a friction point the company intends to eliminate through more advanced automation [2].
Dallara said the goal is to create a device that manages the condition with minimal human intervention [1]. This approach mirrors the evolution of the automotive industry, where driver-assistance features are gradually replaced by full autonomy [1].
While the company did not provide a specific timeline for the release of this fully automated system, the focus remains on reducing the daily mental load for users [2]. The transition to a self-managing system would represent a significant leap in how chronic conditions are treated in the U.S. and globally [2].
““We want to be the self-driving car of insulin pumps.””
The move toward 'autonomous' medical devices reflects a broader trend in healthcare technology to reduce human error and patient burnout. If successful, MiniMed's approach could shift the standard of care from 'patient-managed' to 'system-managed,' potentially increasing adherence and stability in glucose levels for millions of users.
